

Supplementary Table 4. Bivariate Analyses Comparisons of WPAI among Treated UC Patients by Subgroups

Subgroup	Absenteeism % (n = 168) ^a			Presenteeism % (n = 185) ^a			Overall work impairment % (n = 167) ^a			Activity impairment % (n = 293)			
	No.	Mean	SD	No.	Mean	SD	No.	Mean	SD	No.	Mean	SD	
Medication class	5-ASA mono	119	3.4	11.8	131	25.3	27.7	119	26.8	29.1	197	24.0	26.6
	Steroid	18	15.8	30.7	19	33.2	26.3	17	33.8	30.3	34	39.7	30.4
	IM/IS	6	7.7	10.8	6	40.0	29.7	6	42.3	32.2	14	47.1	33.8
	Biologics/JAKi	15	6.9	13.9	18	41.1	30.7	15	40.5	33.3	30	35.3	31.7
	Other	10	13.2	27.3	11	17.3	23.3	10	27.6	30.4	18	15.6	22.8
Severity of UC ^b	Mild	109	3.5	12.4	123	20.4	24.1	109	21.7	25.9	191	20.8	24.3
	Moderate	52	10.1	22.6	54	41.5	30.8	51	43.3	32.5	84	41.9	31.7
	Severe	7	7.6	14.3	8	45.0	23.3	7	46.1	26.9	18	32.2	32.3
Age (yr)	18–39	47	7.5	17.2	55	31.3	28.1	46	34.9	30.0	86	33.0	30.1
	40–64	99	4.7	16.5	107	27.1	28.2	99	28.2	29.9	150	26.5	28.1
	≥ 65	22	6.9	15.5	23	21.3	26.7	22	23.0	28.4	57	22.1	26.9
Sex	Male	112	5.7	16.5	122	29.9	28.9	111	30.6	29.8	163	29.4	28.9
	Female	56	5.9	16.6	63	23.2	25.9	56	26.9	30.0	130	25.2	28.2
Employment status	Employed	168	5.7	16.5	185	27.6	28.0	167	29.3	29.8	188	26.7	27.9
	Unemployed										105	29.1	30.0
Medication adherence ^c	High (≥ 80%)	92	2.4	9.3	104	23.1	26.8	92	22.8	27.3	176	24.3	27.3
	Low (< 80%)	29	12.5	21.1	30	40.7	27.7	29	47.9	28.7	34	40.9	26.8
Time since diagnosis (yr)	< 5	44	6.5	20.7	52	28.3	29.0	43	27.4	30.8	83	28.8	30.7
	5–14	64	1.7	6.5	69	26.1	28.6	64	26.7	29.0	105	23.2	26.8
	≥ 15	49	9.3	20.5	52	26.7	26.0	49	32.3	29.9	85	26.5	26.4

^aThe sample sizes pertaining to absenteeism, presenteeism, and overall work impairment rely on respondents who provided responses to relevant questionnaires within the employed patient population.

^bThe level of self-reported severity of condition when using medication.

^cThe amount of prescribed UC medication taken in the past 4 weeks.

WPAI, work productivity and activity impairment; UC, ulcerative colitis; SD, standard deviation; 5-ASA mono, 5-aminosalicylic acid monotherapy; IM/IS, immunomodulator/immunosuppressant; JAKi, Janus kinase inhibitors.